Kensey Nash touts TriActiv FX results
This article was originally published in The Gray Sheet
Executive Summary
The 3.2% major adverse cardiac event (MACE) rate seen in the firm's prospective ASPIRE registry "is the lowest recorded to date from a sizable multi-center study of the [saphenous vein graft] population, and is less than half of the next best data set widely quoted by the cardiology community," the company said March 7. The results also demonstrate a 2.2% incidence of heart attacks with the TriActiv FX embolic protection system. Kensey Nash will showcase the registry data at the American College of Cardiology meeting in Atlanta this week (1"The Gray Sheet" Feb. 6, 2006, p. 10)...